期刊
BMC NEUROLOGY
卷 10, 期 -, 页码 -出版社
BMC
DOI: 10.1186/1471-2377-10-108
关键词
-
资金
- Fondo de Investigacion Sanitaria (FIS) [PI060155, PI0901636]
- Fundacion Investigacion Medica Mutua Madrilena, CIBERNED [2006.125]
Background: Simple, non-invasive tests for early detection of degenerative dementia by use of biomarkers are urgently required. However, up to the present, no validated extracerebral diagnostic markers for the early diagnosis of Alzheimer disease (AD) are available. The clinical diagnosis of probable AD is made with around 90% accuracy using modern clinical, neuropsychological and imaging methods. A biochemical marker that would support the clinical diagnosis and distinguish AD from other causes of dementia would therefore be of great value as a screening test. A total of 126 samples were obtained from subjects with AD, and age-sex-matched controls. Additionally, 51 Parkinson's disease (PD) patients were used as an example of another neurodegenerative disorder. We analyzed saliva and plasma levels of beta amyloid (A beta) using a highly sensitive ELISA kit. Results: We found a small but statistically significant increase in saliva A beta(42) levels in mild AD patients. In addition, there were not differences in saliva concentration of A beta(42) between patients with PD and healthy controls. Saliva A beta(40) expression was unchanged within all the studied sample. The association between saliva A beta(42) levels and AD was independent of established risk factors, including age or Apo E, but was dependent on sex and functional capacity. Conclusions: We suggest that saliva A beta(42) levels could be considered a potential peripheral marker of AD and help discrimination from other types of neurodegenerative disorders. We propose a new and promising biomarker for early AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据